aTyr Pharma receives orphan drug designation for Resolaris from European Commission
aTyr Pharma receives orphan drug designation for Resolaris from European Commission
About this item
Full title
aTyr Pharma receives orphan drug designation for Resolaris from European Commission
Publisher
London: Normans Media Ltd
Journal title
M2 Pharma, 2015
Language
English
Formats
Publication information
Publisher
London: Normans Media Ltd
Subjects
More information
Scope and Contents
Contents
M2PHARMA-February 20, 2015-aTyr Pharma receives orphan drug designation for Resolaris from European Commission (C)2015 M2 COMMUNICATIONS http://www.m2.com aTyr Pharma, a United States-based biotherapeutics company, has received orphan drug designation from the European Commission for its investigation...
Alternative Titles
Full title
aTyr Pharma receives orphan drug designation for Resolaris from European Commission
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_1656255055
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_1656255055
How to access this item
Log in as a Library member
